Purpose: Peritoneal seeding of gastric cancer is known to have a poor prognosis. With the diagnosis of peritoneal seeding, there is no effective treatment modality. Gastrectomy with chemotherapy or primary chemotherapy is basically one of major options for this condition. This study was conducted to compare the clinical outcomes of these treatments and to identify the better way to improve the prognosis of patients with peritoneal seeding. Materials and Methods: Between 2001 and 2007, gastric cancer patients with peritoneal seeding by preoperative or intraoperative diagnosis were reviewed retrospectively. The enrolled patients were divided as primary gastrectomy and primary chemotherapy group. Clinicopathologic characteristics and clinical outcomes of groups were analyzed and compared. Results: Fifty-four patients were enrolled. 21 patients belonged to the group of primary gastrectomy and 33 patients were to the primary chemotherapy group. Among 33 patients of the primary chemotherapy group, 17 patients were received only chemotherapy and 16 patients were received gastrectomy due to the good responses of primary chemotherapy. The 3 years survival rates were 14% in primary gastrectomy group, 55% in patients who received gastrectomy after primary chemotherapy, and 0% in patients with primary chemotherapy only. Conclusions: Although this study had many limitations, some valuable information was produced. In terms of survival benefits for the gastric cancer patients with peritoneal seeding, primary gastrectomy and additional gastrectomy after primary chemotherapy revealed the better clinical outcomes. But, prospective randomized clinical study and multi-center study are should be performed to decide proper treatment for gastric cancer patients with peritoneal seeding.
Introduction
The prevalence of early stage of gastric cancer patients is increasing annually due to popularization of gastroscopy and these are treated with various methods at early stage of the disease depending on how progressive the disease is. However, when the disease progresses continuously or recurrence, peritoneal seeding is commonly observed during the pathological course and this causes a major concern during the treatment and poor prognosis.
The survival time of gastric cancer patients with peritoneal seeding is reported to be 3~9 months.(1-3) Although managements such as systematic chemotherapy, peritonectomy, intra-peritoneal chemotherapy and heat therapy are applied to improve the prognosis of advanced gastric cancer with peritoneal seeding, satisfactory methods has not yet found. (4, 5) Recently, neo-adjuvant chemotherapy has been applied in various cancers and the results of neoadjuvant chemotherapy have been satisfactory. Therefore, primary chemotherapy is applicable for gastric cancer patients. (6, 7) In gastric cancer, the concept of primary chemotherapy is recognized as a contemporary form of treatment for advanced gastric cancer patients who are too difficult to undergo radical gastrectomy and it has been reported in numerous research that a better prognosis is expected if gastrectomy is done to the patients who had a good response to primary chemotherapy. (8, 9) The research findings are continuously shown that when primary gastrectomy was performed actively prior to chemotherapy, the response to the chemotherapy increased and resulted in the improved prognosis.(10-12) Therefore, the careful consideration is required to choose a treatment option between primary chemotherapy and primary gastrectomy.
Although the status of the disease at the time of diagnosis is an important variable to make a decision, the clinical outcomes of each treatment can be also considered when the decision is made. The researchers in this study intend to provide the clinical outcomes that need to be aware of to choose treatment plans for the gastric cancer patients with peritoneal seeding after comparing the clinical condition and the prognosis of the patients who had primary chemotherapy to those of the patients who had primary gastrectomy among the gastric cancer patients with peritoneal seeding.
Materials and Methods
The subjects were the patients in this hospital who diagnosed metastatic gastric cancer with P1 or P2, but no further metastasis, between January 2001 and December 2007. The patients who had further metastasis to other organs or the patients who were in P3 stage of peritoneal seeding were excluded from this study.
Peritoneal seeding was diagnosed by laparoscopic exploration and it was performed when peritoneal seeding was suspected preoperatively by serosal invasion, thick peritoneum or ascites which can be found on abdominal computerized tomography. The cases which the diagnosis was made after incision of upper abdominal median line but yet peritoneal seeding was not suspected preoperatively were all also included.
In terms of treatment choice, gastrectomy was performed as far as possible, except that it was not impossible to do surgical dissection and excision due to conglomeration caused by infiltration to other organs (T4). Also, gastrectomy was performed for chronic bleeding or obstruction from primary tumor site. All the patients who had gastrectomy also underwent chemotherapy afterwards. If there is evidence that the primary tumor and the condition of inside peritoneum is improving on the above examination, laparoscopic exploration was performed once again to confirm the status of peritoneal seeding. Providing it is judged to be improved, gastrectomy was performed additionally but, supposing the patients didn't respond to the chemotherapy or it showed the evidence of deterioration, continued with chemotherapy after changing its formula instead of doing gastrectomy ( analysis, Chi-square test for Cross tabulation Analysis, KaplanMeier method for survival analysis and the significance was proved wit log-rank test and it is regarded as statistically significant if Pvalue is less than 0.05 (P＜0.05 ).
Results
The total number of patients was 54 people. 21 patients were in the primary gastrectomy group and 33 patients were in the primary chemotherapy group and the male versus female ratio was 2 : 1 and 1.8 : 1 respectively. The age ranged between 32 years old and 75 years old and the average age was 53 years old. The average age of the primary gastrectomy group was 54.9 years old and that of the primary chemotherapy was 56.2 years old showing no significant difference ( Table 1 ).
The stage of peritoneal seeding (P) was evaluated referencing Japanese Classification of Gastric Carcinoma. (13) Table 1 shows the range. There was no significant difference in the proportion of P between two groups. 17 patients from the primary chemotherapy group did not show any signs of improvement and subsequently, they were not received to have gastrectomy and continued with only chemotherapy. The other 16 patients from the same group showed the improvement on the examinations and they had gastrectomy after 2~12 months (5.6 months in average) since the treatment started. Splenectomy was performed with gastrectomy to 3 cases from the primary gastrectomy group and 4 cases from the primary chemotherapy group. Comparing clinicopathologic characteristics of each group after performing gastrectomy, the average tumor size, Borrmann's type, invasion depth and the stage of lymph node showed no significant difference. The degree of histodifferentiation showed both undifferentiated forms in both groups ( Table 2 ).
The tracing period was 36±12 months and the total 3 year survival rate was 21.3%. The 3 year survival rate of the patients who had additional gastrectomy from the primary chemotherapy group was 55.3% and the average survival time was 36 months and the 3 year survival rate of the primary gastrectomy group was 14.2% and the survival time was 20 months. The survival rate of the patients who continued chemotherapy from the primary chemotherapy group was 0% and the average survival time was 10 months; statistically significant differences were evident between the groups (Fig.   2) .
No operation or chemotherapy related mortality or morbidity were found among the patients.
Discussion
In recent years, although the number of early stage of gastric patients is increasing, advanced cases are still found and if there is peritoneal seeding, the prognosis can be poor.
Because of the poor prognosis, standard conventional chemotherapy would be preferably considered, however, intra-peritoneal and systemic combined chemotherapy, intra-peritoneal heat The total 3 year survival rate was 21.3% in this study but, comparing to this, the total 3 year survival rate was reported to be about 15% in the study of Yonemura et al. (20) and was reported to be about 18% in the study of Glehen et al. (21) . In detail, the 3 year survival rate of the patients who had gastrectomy after primary chemotherapy was 55.3% in this study and Yonemura et al. (20) also reported more than 50% but Badgwell et al. (22) reported only 12% in their study. The 3 year survival rate in the primary gastrectomy group was 14.2% in this study and it was 12.9% in the study of Hioki et al. (23) . It was 0% in the patients who continued with alternative chemotherapy according to the result of response test and Badgwell et al. (22) also reported the same figure. Although research methods, difference between the group of patients and treatment methods were rather different in all those studies, the survival rate in this study was similar to the other studies overall.
When gastric cancer patients had unexpected peritoneal seeding after exploration, it was inevitable to close without any procedure.
However, the researchers in this study tried to do gastrectomy and gastrectomy with other excision, peritonectomy and D2 above lymph node dissection as long as possible. Kwon(24) and Seo et al. (25) claimed that radical curability could be achieved by gastrec- More researches regarding appropriate primary treatments for the patient with peritoneal seeding are thought to be required because it is possible that primary gastrectomy might be more beneficial for them in terms of the prognosis. Therefore, it is necessary to compare between the efficacy of primary chemotherapy and primary gastrectomy with well-designed prospective randomized clinical study.
There are some limitations in this study. First of all, because the size and the depth of primary lesion, Borrmann's type and the level of affected lymph node were largely different, there can be a lack of consideration on these factors. Additionally, it can be less objective to judge the conglomeration status that makes impossible to operate gastrectomy when the decision is made to do primary gastrectomy. Finally, there is a possibility for subjective interference when the response to chemotherapy was evaluated with the results of gastroscopy, abdominal CT and PET because the unique Korean standard and the international standard to judge the response of chemotherapy are ambiguous. Hence, the objective and detailed standard to judge the response of chemotherapy in gastric cancer is necessary. Currently, the combination chemotherapy is the most commonly used in chemotherapy for gastric cancer and the formula of this vary depending on clinician. As a result, it is not feasible to decide a treatment depending on the response after having chemotherapy under circumstances where there is no objectification for the formula.
Although it is difficult to generalize the results of this study, it is thought to be beneficial to perform gastrectomy actively when feasible.
To improve prognosis of gastric cancer patients with peritoneal seeding, when these patients receive primary chemotherapy, it is important to actively consider gastrectomy, depending on the response to chemotherapy.
It is also necessary to make comparison between the efficacy of primary chemotherapy and that of primary gastrectomy through well-designed prospective randomized clinical study in order to establish the treatment guidance for the gastric cancer with peritoneal seeding.
